N. Tassopoulos

651 total citations
27 papers, 486 citations indexed

About

N. Tassopoulos is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, N. Tassopoulos has authored 27 papers receiving a total of 486 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Hepatology, 22 papers in Epidemiology and 2 papers in Infectious Diseases. Recurrent topics in N. Tassopoulos's work include Hepatitis C virus research (20 papers), Hepatitis B Virus Studies (19 papers) and Liver Disease Diagnosis and Treatment (12 papers). N. Tassopoulos is often cited by papers focused on Hepatitis C virus research (20 papers), Hepatitis B Virus Studies (19 papers) and Liver Disease Diagnosis and Treatment (12 papers). N. Tassopoulos collaborates with scholars based in Greece, United States and Australia. N. Tassopoulos's co-authors include Angelos Hatzakis, Giota Touloumi, Vana Sypsa, G. Papaevangelou, Robert H. Purcell, John R. Ticehurst, M. Malliori, C. Stefanis, Mina Psichοgiou and Athanasios Skoutelis and has published in prestigious journals such as The Lancet, Gut and Journal of Clinical Microbiology.

In The Last Decade

N. Tassopoulos

27 papers receiving 457 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
N. Tassopoulos Greece 14 365 353 94 27 23 27 486
Ángeles Castro‐Iglesias Spain 12 227 0.6× 222 0.6× 247 2.6× 9 0.3× 9 0.4× 35 458
Jeffrey S. Murray United States 13 322 0.9× 291 0.8× 355 3.8× 10 0.4× 16 0.7× 31 729
Mohammad Arif Saudi Arabia 12 410 1.1× 388 1.1× 131 1.4× 5 0.2× 8 0.3× 34 577
Haesun Yun South Korea 13 144 0.4× 299 0.8× 179 1.9× 3 0.1× 25 1.1× 28 405
Mas Chaponda United Kingdom 12 323 0.9× 85 0.2× 156 1.7× 22 0.8× 5 0.2× 21 554
Leire Pérez‐Latorre Spain 10 201 0.6× 112 0.3× 158 1.7× 22 0.8× 2 0.1× 27 345
К. В. Жданов Russia 9 191 0.5× 133 0.4× 93 1.0× 14 0.5× 7 0.3× 85 273
JM Miró Spain 8 135 0.4× 76 0.2× 199 2.1× 13 0.5× 10 0.4× 14 355
Annemie Buelens Belgium 10 234 0.6× 222 0.6× 268 2.9× 36 1.3× 9 0.4× 19 438
Ewa Siwak Poland 9 157 0.4× 137 0.4× 111 1.2× 3 0.1× 15 0.7× 24 372

Countries citing papers authored by N. Tassopoulos

Since Specialization
Citations

This map shows the geographic impact of N. Tassopoulos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Tassopoulos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Tassopoulos more than expected).

Fields of papers citing papers by N. Tassopoulos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. Tassopoulos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Tassopoulos. The network helps show where N. Tassopoulos may publish in the future.

Co-authorship network of co-authors of N. Tassopoulos

This figure shows the co-authorship network connecting the top 25 collaborators of N. Tassopoulos. A scholar is included among the top collaborators of N. Tassopoulos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. Tassopoulos. N. Tassopoulos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Manolakopoulos, Spilios, Giorgos Bakoyannis, George Papatheodoridis, et al.. (2014). Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study.. Europe PMC (PubMed Central). 6 indexed citations
2.
Lim, Seng Gee, Patrick Marcellin, N. Tassopoulos, et al.. (2007). Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B. Alimentary Pharmacology & Therapeutics. 26(10). 1419–1428. 26 indexed citations
3.
Sypsa, Vana, Giota Touloumi, George Papatheodoridis, et al.. (2005). Future trends of HCV‐related cirrhosis and hepatocellular carcinoma under the currently available treatments. Journal of Viral Hepatitis. 12(5). 543–550. 24 indexed citations
4.
Sypsa, Vana, Giota Touloumi, N. Tassopoulos, et al.. (2004). Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection. Journal of Viral Hepatitis. 11(4). 366–374. 37 indexed citations
5.
Hadziyannis, S., N. Tassopoulos, Jenny Heathcote, et al.. (2003). Two year results from a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B. Journal of Hepatology. 38. 143–143. 14 indexed citations
6.
Tassopoulos, N., Stephanos J. Hadziyannis, G. Idéo, et al.. (2000). Famciclovir treatment of anti-HBE+ chronic hepatitis B: Results of a randomized, placebo-controlled study. Journal of Hepatology. 32. 102–102. 4 indexed citations
7.
Malliori, M., Vana Sypsa, Mina Psichοgiou, et al.. (1998). A survey of bloodborne viruses and associated risk behaviours in Greek prisons. Addiction. 93(2). 243–251. 91 indexed citations
8.
Delladetsima, Johanna K., et al.. (1995). Ductular structures in acute hepatitis with panacinar necrosis. The Journal of Pathology. 175(1). 69–76. 10 indexed citations
9.
Papatheodoridis, George, et al.. (1995). Clinicopathological assessment of hepatitis C virus infection in parenteral drug abusers.. PubMed. 90(10). 1843–6. 6 indexed citations
10.
Tassopoulos, N., et al.. (1994). HBcAg and HBsAg expression in ductular cells in chronic hepatitis B. Liver International. 14(2). 71–75. 16 indexed citations
11.
Tassopoulos, N., et al.. (1993). Recombinant human interferon alfa-2b treatment for acute non-A, non-B hepatitis.. Gut. 34(2 Suppl). S130–S132. 27 indexed citations
12.
Tassopoulos, N., Maria H. Sjögren, & Robert H. Purcell. (1990). 19S and 7-8S forms of IgM antibody to hepatitis B core antigen in acute icteric hepatitis superimposed on hepatitis B surface antigen carriage. Infection. 18(6). 376–380. 3 indexed citations
13.
Tassopoulos, N., R H Purcell, Georgios Théodoropoulos, Maria H. Sjögren, & Ronald E. Engle. (1989). Serological markers of hepatitis B virus and hepatitis D virus infections in Greek adults with primary hepatocellular carcinoma. Infection. 17(1). 17–19. 4 indexed citations
14.
Roumeliotou‐Karayannis, A., et al.. (1987). Prevalence of HBV, HDV and HIV infections among intravenous drug addicts in Greece. European Journal of Epidemiology. 3(2). 143–6. 19 indexed citations
15.
Tassopoulos, N., et al.. (1986). Serologic markers of hepatitis B virus (HBV) and hepatitis D virus infection in carriers of hepatitis B surface antigen who are frequently exposed to HBV.. PubMed. 33(4). 151–4. 1 indexed citations
16.
Tassopoulos, N., G. Papaevangelou, John R. Ticehurst, & Robert H. Purcell. (1986). Fecal Excretion of Greek Strains of Hepatitis A Virus in Patients with Hepatitis A and in Experimentally Infected Chimpanzees. The Journal of Infectious Diseases. 154(2). 231–237. 46 indexed citations
17.
Roumeliotou‐Karayannis, A., et al.. (1985). How often does chronic liver disease follow acute hepatitis B in adults?. Infection. 13(4). 174–176. 15 indexed citations
18.
Roumeliotou‐Karayannis, A., et al.. (1985). Evaluation of methods of pre-vaccination screening for markers of hepatitis B infection. European Journal of Epidemiology. 1(2). 100–103. 3 indexed citations
19.
Roumeliotou‐Karayannis, A., N. Tassopoulos, Richard S. Tedder, et al.. (1983). HEPATITIS B VACCINATION POLICY. The Lancet. 321(8323). 533–534. 4 indexed citations
20.
Hn, Kirkman, et al.. (1965). DIVERSE CHARACTERISTICS OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE FROM GREEK CHILDREN.. PubMed. 65. 212–21. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ángeles Castro‐Iglesias Breakdown of academic impact, for papers by Jeffrey S. Murray Breakdown of academic impact, for papers by Mohammad Arif Breakdown of academic impact, for papers by Haesun Yun Breakdown of academic impact, for papers by Mas Chaponda Breakdown of academic impact, for papers by Leire Pérez‐Latorre Breakdown of academic impact, for papers by К. В. Жданов Breakdown of academic impact, for papers by JM Miró Breakdown of academic impact, for papers by Annemie Buelens Breakdown of academic impact, for papers by Ewa Siwak
Rankless by CCL
2026